Establishing a European Medicine Supply Chain Research Network

The MIA project hosted a two-day hybrid event, 15 to 16 May held at BI Norwegian Business School – campus Oslo.

The Measures for Improved Availability of Medicines and Vaccines (MIA) project brought together European medicine supply chain actors, medicine regulators and researchers to disseminate key project insights, engage in ongoing research and to take steps towards the establishment of a European Medicine Supply Chain Research Network, during a two-day hybrid event, 15 to 16 May held at BI Norwegian Business School – campus Oslo.

Presentations from the event and the recordings from the hybrid sessions are provided below.

Day one – Stakeholders and Policy Makers

MIA researchers and The Norwegian Hospital Procurement Trust presented key research and tools to improve medicine availability, to international researchers and stakeholders including the Norwegian Medical Products Agency, Norwegian Pharmacy Association, Farma Norge, Association of the Pharmaceutical Industry in Norway, Norwegian Directorate of Health, National Centre for Medicine Shortages and Medicine Preparedness in Specialist Health Services and Norsk Medisinaldepot AS, and representatives from the UK and the Netherlands, who joined us online.

Day two – Researchers

Norwegian, EU, UK, US, and Ethiopian researchers shared relevant ongoing and potential research. We agreed to collaborate further and take steps to advance a European Medicine Supply Chain Research Network to develop resilient, sustainable supply chains and provide evidence-based support to decision-makers.

Presentations from the sessions

- Welcome (Karen Spens and Marianne Jahre, BI Norwegian Business School)
- Improving Access for Drugs: The A4D Framework (Thomas Breugem, Tilburg University)
  - Link to the Working Paper
- Systems view of generic medicine shortages – how one intervention impacts another (Kim van Oorschot, BI Norwegian Business School)
  - Link to paper
- Increased knowledge in SCM for pharmaceutical students (Anne Berit Walter, Oslo Met)
- A closer look at price hikes in the Norwegian market for off-patent medicines (Dag Morten Dalen, BI Norwegian Business School)